Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.55 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.55 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | INSR | P06213 | 1/20 | 0.48 |
| ▸ | IGF1R | P08069 | 1/20 | 0.48 |
| ▸ | SRC | P12931 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16312135 | 0.87 | TAAR1 (0.58) | TAAR1SLC6A4SLC6A2SLC6A3CYP3A4 | |
| SCHEMBL29417378 | 0.79 | HPGD (0.51) | TAAR1SLC6A4SLC6A2SLC6A3CYP3A4 | |
| SCHEMBL4168491 | 0.78 | TAAR1 (0.70) | TAAR1SLC6A4SLC6A2SLC6A3CYP3A4 | |
| SCHEMBL4168488 | 0.78 | TAAR1 (0.70) | TAAR1SLC6A4SLC6A2SLC6A3CYP3A4 | |
| SCHEMBL4170645 | 0.78 | TAAR1 (0.70) | TAAR1SLC6A4SLC6A2SLC6A3CYP3A4 | |
| SCHEMBL30147114 | 0.78 | TAAR1 (0.70) | TAAR1SLC6A4SLC6A2SLC6A3CYP3A4 | |
| SCHEMBL11693746 | 0.78 | HRH2 (0.55) | TAAR1SLC6A4SLC6A2SLC6A3CYP3A4 | |
| SCHEMBL16312618 | 0.78 | HRH2 (0.55) | TAAR1SLC6A4SLC6A2SLC6A3CYP3A4 | |
| SCHEMBL108372 | 0.77 | TAAR1 (0.58) | TAAR1SLC6A4SLC6A2SLC6A3CYP3A4 | |
| SCHEMBL29664514 | 0.75 | TAAR1 (0.57) | TAAR1SLC6A4SLC6A2SLC6A3CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200368169-A1 | ABUSE-DETERRENT COMPOSITIONS | PATHEON SOFTGELS INC (US) | 2020-11-26 | — | — | US | disclosed |
| US-10772842-B2 | Abuse-deterrent opioids | PATHEON SOFTGELS INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-10772841-B2 | Opioid abuse-deterrent controlled release formulations | PATHEON SOFTGELS INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-10639301-B2 | Use of flecainide as an anti-connexin agent and method for potentiating the effects of a psychotropic drug | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2020-05-05 | — | — | US | disclosed |
| US-10478429-B2 | Abuse deterrent dosage forms | Patheon Softgels, Inc. (US) | 2019-11-19 | — | — | US | disclosed |
| US-10335405-B1 | Non-burst releasing pharmaceutical composition | Patheon Softgels, Inc. (US) | 2019-07-02 | — | — | US | disclosed |
| US-10226432-B2 | Enteric soft capsule compositions | PATHEON SOFTGELS INC. (US) | 2019-03-12 | — | — | US | disclosed |
| US-10182992-B2 | Abuse-deterrent controlled release formulations | PATHEON SOFTGELS INC. (US) | 2019-01-22 | — | — | US | disclosed |
| US-20190008844-A1 | Use of Flecainide as an Anti-Connexin Agent and Method for Potentiating the Effects of a Psychotropic Drug | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2019-01-10 | — | — | US | disclosed |
| US-10105321-B2 | Pharmaceutical compositions resistant to abuse | EGALET LTD. (GB) | 2018-10-23 | — | — | US | disclosed |
| WO-2010149169-A2 | CONTROLLED RELEASE FORMULATIONS | EGALET A/S (DK) | 2010-12-29 | — | — | WO | disclosed |
| US-20100239667-A1 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS FOR PROLONGED EFFECT | EGALET A/S (DK) | 2010-09-23 | — | — | US | disclosed |
| WO-2010088911-A1 | PHARMACEUTICAL COMPOSITIONS RESISTANT TO ABUSE | EGALET A/S (DK) | 2010-08-12 | — | — | WO | disclosed |
| US-20100203130-A1 | PHARMACEUTICAL COMPOSITIONS RESISTANT TO ABUSE | EGALET A/S (DK) | 2010-08-12 | — | — | US | disclosed |
| WO-2010089132-A1 | IMMEDIATE RELEASE COMPOSITION RESISTANT TO ABUSE BY INTAKE OF ALCOHOL | EGALET A/S (DK) | 2010-08-12 | — | — | WO | disclosed |
| US-20100203129-A1 | CONTROLLED RELEASE FORMULATIONS WITH CONTINUOUS EFFICACY | EGALET A/S (DK) | 2010-08-12 | — | — | US | disclosed |
| US-20100204259-A1 | IMMEDIATE RELEASE COMPOSITION RESISTANT TO ABUSE BY INTAKE OF ALCOHOL | EGALET A/S (DK) | 2010-08-12 | — | — | US | disclosed |
| WO-2010083843-A1 | CONTROLLED RELEASE FORMULATIONS WITH CONTINUOUS EFFICACY | EGALET A/S (DK) | 2010-07-29 | — | — | WO | disclosed |
| EP-2155167-A2 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS FOR PROLONGED EFFECT | Egalet A/S (DK) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008148798-A2 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS FOR PROLONGED EFFECT | EGALET A/S (DK) | 2008-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10639301-B2 | Use of flecainide as an anti-connexin agent and method for potentiating the effects of a psychotropic drug | GJA1, GJB2, GAP43 | TAAR1 1165/4885SLC6A4 637/4885SLC6A2 317/4885 |
| US-20190008844-A1 | Use of Flecainide as an Anti-Connexin Agent and Method for Potentiating the Effects of a Psychotropic Drug | GJA1, GJB2, GAP43 | TAAR1 1165/4885SLC6A4 637/4885SLC6A2 317/4885 |
| US-20100203130-A1 | PHARMACEUTICAL COMPOSITIONS RESISTANT TO ABUSE | OPRK1, CES2, OPRM1 | TAAR1 441/4885SLC6A4 85/4885SLC6A2 43/4885 |
| US-20100204259-A1 | IMMEDIATE RELEASE COMPOSITION RESISTANT TO ABUSE BY INTAKE OF ALCOHOL | ADH1C, ADH1A, ADH5 | TAAR1 33/4885SLC6A4 355/4885SLC6A2 84/4885 |
| US-20100203129-A1 | CONTROLLED RELEASE FORMULATIONS WITH CONTINUOUS EFFICACY | ABCB11, CRH, LPXN | TAAR1 1377/4885SLC6A4 245/4885SLC6A2 57/4885 |
| US-10105321-B2 | Pharmaceutical compositions resistant to abuse | OPRK1, CES2, OPRM1 | TAAR1 441/4885SLC6A4 85/4885SLC6A2 43/4885 |
| US-20100239667-A1 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS FOR PROLONGED EFFECT | SI, GIPR, MLN | TAAR1 2115/4885SLC6A4 2559/4885SLC6A2 2547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.